Psoriasiform exfoliative erythroderma induced by golimumab

Clinical and Experimental Dermatology

Volumn 39, Issue 7, 2014, Pages 813-815

  Mateo, Sandra ^a   Garcia Martinez F J ^a   Sanchez Aguilar D ^a   Amarelo, J ^a   Toribio, J ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; LEFLUNOMIDE; PREDNISONE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACANTHOSIS; ADULT; ARTICLE; CASE REPORT; DESQUAMATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EOSINOPHILIA; EXOCYTOSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; KERATINOCYTE; LEUKOCYTOSIS; MALE; MIDDLE AGED; PARAKERATOSIS; PRIORITY JOURNAL; PSORIASIFORM EXFOLIATIVE ERYTHRODERMA; PSORIATIC ERYTHRODERMA; RASH; RHEUMATOID ARTHRITIS; SKIN BIOPSY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; ERYTHRODERMA;

ANTIBODIES, MONOCLONAL; DERMATITIS, EXFOLIATIVE; HUMANS; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927513349     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12402     Document Type: Article

References (10)

1. Shmidt E, Wetter DA, Ferguson SB et al. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-a inhibitors: The Mayo clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67: 179-85.
2. Davaine AC, Saraux A, Prigent S et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: A cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 1471-7.
3. Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58: 1033-9.
4. Collamer AN, Battafarano DF. Psoriasis skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233-40.
5. Shelling ML, Vitiello M, Lanuti EL et al. A case of palmoplantar pustulosis induced by certolizumab pegol: New anti-TNF-alpha demonstrates the same class effect. J Clin Aesthet Dermatol 2012; 5: 40-1.
6. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanism of action. Arthritis Rheum 2008; 59: 996-1001.
7. Zidi I, Bartegi A, Ben AN. Dermatologic adverse events: Golimumab, friend or foe? Pharmazie 2011; 66: 5-10.
8. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: Is it really a paradoxical side effect? Clin Exp Rheumatol 2012; 30: 700-6.
9. Wollina U, Hansel G, Koch A et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14.
10. Seneschal J, Lepreux S, Bouyssou-Gauthier ML et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. Acta Derm Venereol 2007; 87: 77-80.